Navigation Links
Protein therapy may reduce infarct size in heart attack patients

Researchers are searching for new methods and therapies to reduce infarct size and improve blood flow to the heart muscle in patients who experience myocardial infarction (MI), or heart attack.

In a study presented today at the American College of Cardiology’s Innovation in Intervention: i2 Summit in New Orleans, La., a team from the Duke Clinical Research Institute presented the results from a Phase 1 study evaluating a novel protein kinase C inhibitor that had shown benefit in animal models, but had not previously been studied in humans. This first-in-human study suggests that this new drug may have promise as a potential therapeutic agent in heart attack patients. Innovation in Intervention: i2 Summit is an annual meeting for practicing cardiovascular interventionalists sponsored by the American College of Cardiology in partnership with the Society for Cardiovascular Angiography and Interventions.

Heart attacks are caused by blockages in the coronary artery preventing blood flow to the heart muscle. Restoring blood flow to the heart improves clinical outcomes in heart attack patients, but there remains significant injury to heart muscle cells. Protein kinase C (PKC) is activated in these heart cells, initiating a series of events that can cause further damage to the heart. Animal studies have suggested that KAI-9803, an inhibitor of PKC, may reduce injury in damaged heart muscle cells, but this class of therapies had not previously been studied in heart attack patients.

In the DELTA MI trial, the DCRI team evaluated KAI-9803 in 154 patients with anterior ST-elevation MI undergoing primary percutaneous coronary intervention with balloon angioplasty and coronary stent implantation. Patients were randomized 2:1 to receive intracoronary injections of the active study drug (KAI-9803) vs. placebo in four dose groups (0.05, 0.5, 1.25 or 5.0 mg of KAI-9803). Researchers performed tests to assess heart function at various time points and a ssessed safety and cardiac outcomes through six months. This trial was designed as an exploratory study to assess the potential impact of KAI-9803 in this “first-in-human?study.

Results indicate that KAI-9803 may be associated with less myocardial necrosis with lower CK-MB AUC values at all dose levels. Furthermore, improved tissue perfusion (measured during coronary angiography after stent implantation and by continuous electrocardiogram recordings) and reduced infarct size (measured 14 days after the heart attack) were observed at the 0.5 mg (infarct size 23 vs. 29.5% of the left ventricle) and 1.25 mg (infarct size 32.5 vs. 43% of the left ventricle) dose levels. No major safety concerns were demonstrated with the therapy since the incidence of serious adverse events was similar among patients treated with KAI-9803 compared to placebo, even at the highest dose levels of the study.

"In this early study, we believe the data suggest a potential therapeutic role for KAI-9803,?said Matthew Roe, M.D., of the Duke Clinical Research Institute and lead author of the study. “The drug was associated with a favorable safety and tolerability profile and based on this ‘first in human?trial, we are interested in pursing larger studies to determine the therapeutic value of this treatment for heart attack patients receiving reperfusion therapy."


'"/>

Source:American College of Cardiology


Related biology news :

1. Quantum Dots Research Leads to New Knowledge about Protein Binding in Plants
2. Protein discovery could unlock the secret to better TB treatment
3. Researchers Uncover Key Step In Manufacture of Memory Protein
4. An HIV Protein Plays a Surprising Role in Gene Activation
5. Protein Packages Found To Activate Genes; May Be What Regulates Development And Disease
6. New SARS Protein Linked To Important Cell Doorway
7. The Shapes Of Life: NIGMS Project Yields More Than 1,000 Protein Structures
8. PANTHER Protein Classification System Database 5.0
9. Duke Chemists Isolating Individual Molecules Of Toxic Protein In Alzheimers, Parkinsons Disease
10. Newly Discovered Compound Blocks Known Cancer-Causing Protein
11. UF Researchers Map Bacterial Proteins That Cause Tooth Loss
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/24/2016)... -- Cercacor today introduced Ember TM Sport Premium ... measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion Index, ... approximately 30 seconds. Smaller than a smartphone, using only ... key data about their bodies to help monitor these ... Hemoglobin carries oxygen to muscles. When hemoglobin and ...
(Date:11/19/2016)... Securus Technologies, a leading provider of civil ... corrections and monitoring, announced today that it has offered ... an independent technology judge determine who has the largest ... telephone calling platform, and the best customer service. ... of what we do – which clearly is not ...
(Date:11/15/2016)... ROCKVILLE, Md. , Nov. 15, 2016 /PRNewswire/ ... clinical company developing therapeutics focused on the gut ... public offering of 25,000,000 shares of its common ... its common stock at a price to the ... gross proceeds to Synthetic Biologics from the offering, ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... (PRWEB) , ... December 02, ... ... (ETC), a consortium of pharmaceutical and biotechnology companies dedicated to collaboratively developing ... companies interested in supplying a vendor-supported, portable online UHPLC, with robust, probe-based ...
(Date:12/2/2016)... , December 2, 2016 The ... 2021, growing at a CAGR of 7.3% during the forecast period ... hospitals and diagnostic laboratories segment accounted for the largest share of ... ... report on global immunohistochemistry (IHC) market spread across 225 pages, profiling ...
(Date:11/30/2016)... 30, 2016  GenomOncology today announced the appointment of ... Affairs.  Dr. Coleman will oversee clinical content ... knowledge-enabled platform. The GenomOncology software suite empowers molecular pathologists with ... and clinical decision support, from quality control through reporting. ... , , ...
(Date:11/30/2016)... 2016 Biotest Pharmaceuticals Corporation (BPC), a leading ... the addition of its newest plasma collection center located ... . The 15,200 square foot state-of-the-art facility officially opened ... brings the total number of BPC,s plasma collection centers ... BPC,s Chief Executive Officer said "We are pleased to ...
Breaking Biology Technology: